NCT01374438View on ClinicalTrials.gov

3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

May 31, 2013

Conditions
Alzheimer's Disease
Interventions
DRUG

MSDC-0160

MSDC-0160 150 mg capsules given once daily for 90 days

DRUG

Placebo

Placebo capsules given once daily for 90 days

Trial Locations (1)

60612

Rush Memorial University Medical Center, Chicago

Sponsors
All Listed Sponsors
lead

Metabolic Solutions Development Company

INDUSTRY

NCT01374438 - 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease | Biotech Hunter | Biotech Hunter